Advertisement Daiichi Sankyo' Subsidiary Acquires PharmaForce - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Daiichi Sankyo’ Subsidiary Acquires PharmaForce

PharmaForce product line will be marketed by American Regent

Luitpold Pharmaceuticals, a US subsidiary of Daiichi Sankyo, and PharmaForce have announced that PharmaForce has been acquired by Luitpold.

The FTC cleared the transaction under the Hart-Scott-Rodino Antitrust Improvement Act. As per the agreement, Luitpold purchased 100% of PharmaForce stock and the closing was completed on December 29, 2009. The PharmaForce product line will be marketed by Luitpold’s subsidiary, American Regent.

Mary Jane Helenek, president and CEO of Luitpold, said: “The acquisition of PharmaForce is another important step in the implementation of Luitpold’s strategic plan to further diversify our product portfolio and generate additional growth for Luitpold and its wholly owned subsidiary, American Regent, Inc. This acquisition provides an immediate expansion of our R&D pipeline, increased manufacturing capacity and establishes a base from which to move forward with different injectable dosage forms to take advantage of the fast growing generic injectable market.”

Headquartered in Columbus, Ohio, PharmaForce is focused on the manufacture, development and marketing of difficult to manufacture sterile products and sole source or first-to market generic injectable products.